Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 23Breast 11Plasma cell 7Lymphoid 7Gastrointestinal 4Thoracic 3Other solid neoplasm 3Genitourinary 3Other hematologic neoplasm 2Tumor-Agnostic 1Sarcoma 1Myeloid 1Head & Neck 1Dermatologic 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma 1Leukemia 1

Interventions

Cyclophosphamide 49fludarabine phosphate 42fludarabine 37Azacitidine 35Busulfan 30Whole-Body Irradiation 26Imatinib Mesylate 24Antilymphocyte Serum 24Tacrolimus 23Mycophenolic Acid 22Cytarabine 21Filgrastim 20Peripheral Blood Stem Cell Transplantation 17Methotrexate 17Melphalan 17Cyclosporine 16venetoclax 14thymoglobulin 14Granulocyte Colony-Stimulating Factor 14Thiotepa 12ruxolitinib 11Stem Cell Transplantation 11Decitabine 11Dasatinib 11Alemtuzumab 11nilotinib 10Radiotherapy 10Rituximab 9Cord Blood Stem Cell Transplantation 9ponatinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × liposomal doxorubicin × Myeloid × Clear all
NCT00074490 2018-12-31

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
442 enrolled 17 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡